Gilgamesh Pharmaceuticals Raises $39 Million Series B To Advance Mental Health Treatments
Amount Raised
$39 Million
Round Type
Series B
New YorkHealthcareInvestors
Description
Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health disorders, today announced the closing of a $39 million Series B round of financing. The round was led by Prime Movers Lab with additional investment from Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital and Gron Ventures. The additional capital will be used, in part, to further advance Gilgamesh's 2 lead programs, GM-1020 and GM-2505 through Phase 1/1b safety and efficacy studies.
Quick answer
Gilgamesh Pharmaceuticals raised $39 Million in a Series B round, dated December 15, 2022. Investors: Gron Ventures, Satori Capital, JLS Fund, Negev Capital and Alumni Ventures. Gilgamesh Pharmaceuticals is based in New York, New York, United States.
- How much did Gilgamesh Pharmaceuticals raise?
- Gilgamesh Pharmaceuticals raised $39 Million in a Series B round on December 15, 2022.
- Who invested in Gilgamesh Pharmaceuticals?
- Gron Ventures, Satori Capital, JLS Fund, Negev Capital and Alumni Ventures are named as investors in this round.
- What does Gilgamesh Pharmaceuticals do?
- Gilgamesh is a pioneering, mental health science-focused biotechnology company.
- Where is Gilgamesh Pharmaceuticals based and how big is it?
- Gilgamesh Pharmaceuticals is based in New York, New York, United States.
- Who are the decision-makers at Gilgamesh Pharmaceuticals?
- Fundz holds 1 contact at Gilgamesh Pharmaceuticals, including the VP, Toxicology and ADME. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare around the same time
Companies in the same sectors as Gilgamesh Pharmaceuticals that raised within 45 days of this round, from Fundz verified event records.
- Inhibikase Therapeutics raised $4.2M (Seed) on January 27, 2023.
- Persona Health raised $25K (Pre-Seed) on January 27, 2023.
- WETHRIVV raised $650K (Seed) on January 27, 2023.
- Remedy Diagnostics raised $345K (Seed) on January 27, 2023.
- ADARx Pharmaceuticals, Inc. raised $46M on January 26, 2023.
- Accure Acne raised $8M on January 26, 2023.
Who to call at Gilgamesh Pharmaceuticals, and when
A new round usually means Gilgamesh Pharmaceuticals is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Gilgamesh Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Gilgamesh Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gilgamesh Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gilgamesh Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGilgamesh Pharmaceuticals raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.